HDAC9 and neoplasm: To interrogate whether the HDAC inhibitor and aminopeptidase inhibitor were synergistic as observed in vitro, doses of each agent were chosen that partially inhibited tumour growth (CHR-3996 30 mg/kg, tosedostat 75 mg/kg).